Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. Glenmark is the leader in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). The company has a significant presence in branded generics markets across emerging economies including India. It also has a fast growing and robust US generics business. Its stock is listed on India’s two large stock exchanges, the• Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Glenmark employs nearly 6000 people across its global operations across 80 countries.

Glenmark was recently awarded by SCRIP, the largest selling and most respected pharmaceutical magazine in the world as the “Best Pharma company in the World – SME” and “Best company across Emerging markets” for 2008. Forbes, another leading international publication recognized Glenmark as the “Best Under a Billion Dollar companies in Asia” for 2008.

In the area of drug discovery, Glenmark is focused in the areas of inflammation,metabolic disorders and pain. Presently, Glenmark has eight molecules in clinical trials. Most of them are either best-in-class or first-in-class with each have potential to become global blockbusters. Two of its molecules will enter Phase III trials. With this development, Glenmark takes a step closer to becoming the first Indian company to launch a truly innovative drug globally